> Detailanzeige

Suárez-García, Inés; Moreno, Cristina; Ruiz-Algueró, Marta; Pérez-Elías, María Jesús; Navarro, Marta; Díez Martínez, Marcos; Viciana, Pompeyo; Pérez-Martínez, Laura; Górgolas, Miguel; Amador, Concha; de Zárraga, Miguel Alberto; Jarrín, Inma; Moreno, Santiago; Jarrín, Inma; Dalmau, David; Navarro, Maria Luisa; González, Maria Isabel; Garcia, Federico; Poveda, Eva; Iribarren, Jose Antonio; Gutiérrez, Félix; Rubio, Rafael; Vidal, Francesc; Berenguer, Juan; [...]

Effectiveness of the combination elvitegravir/cobicistat/tenofovir/emtricitabine (EVG/COB/TFV/FTC) plus darunavir among treatment-experienced patients in clinical practice: a multicentre cohort study

Literatur-
verwaltung

Zur
Merkliste

Lösche von
Merkliste

Per Whatsapp teilen

Schließen

Merkliste



Sie können Bookmarks mittels Listen verwalten, loggen Sie sich dafür bitte in Ihr SLUB Benutzerkonto ein.
  • Medientyp: E-Artikel
  • Titel: Effectiveness of the combination elvitegravir/cobicistat/tenofovir/emtricitabine (EVG/COB/TFV/FTC) plus darunavir among treatment-experienced patients in clinical practice: a multicentre cohort study
  • Beteiligte: Suárez-García, Inés; Moreno, Cristina; Ruiz-Algueró, Marta; Pérez-Elías, María Jesús; Navarro, Marta; Díez Martínez, Marcos; Viciana, Pompeyo; Pérez-Martínez, Laura; Górgolas, Miguel; Amador, Concha; de Zárraga, Miguel Alberto; Jarrín, Inma; Moreno, Santiago; Jarrín, Inma; Dalmau, David; Navarro, Maria Luisa; González, Maria Isabel; Garcia, Federico; Poveda, Eva; Iribarren, Jose Antonio; Gutiérrez, Félix; Rubio, Rafael; Vidal, Francesc; Berenguer, Juan; [...]
  • Erschienen: Springer Science and Business Media LLC, 2020
  • Erschienen in: AIDS Research and Therapy
  • Sprache: Englisch
  • DOI: 10.1186/s12981-020-00302-2
  • ISSN: 1742-6405
  • Schlagwörter: Pharmacology (medical) ; Virology ; Molecular Medicine
  • Entstehung:
  • Anmerkungen:
  • Beschreibung: <jats:title>Abstract</jats:title><jats:sec> <jats:title>Background</jats:title> <jats:p>The aim of this study was to investigate the effectiveness and tolerability of the combination elvitegravir/cobicistat/tenofovir/emtricitabine plus darunavir (EVG/COB/TFV/FTC + DRV) in treatment-experienced patients from the cohort of the Spanish HIV/AIDS Research Network (CoRIS).</jats:p> </jats:sec><jats:sec> <jats:title>Methods</jats:title> <jats:p>Treatment-experienced patients starting treatment with EVG/COB/TFV/FTC + DRV during the years 2014–2018 and with more than 24 weeks of follow-up were included. TFV could be administered either as tenofovir disoproxil fumarate or tenofovir alafenamide. We evaluated virological response, defined as viral load (VL) &lt; 50 copies/ml and &lt; 200 copies/ml at 24 and 48 weeks after starting this regimen, stratified by baseline VL (&lt; 50 or ≥ 50 copies/ml at the start of the regimen).</jats:p> </jats:sec><jats:sec> <jats:title>Results</jats:title> <jats:p>We included 39 patients (12.8% women). At baseline, 10 (25.6%) patients had VL &lt; 50 copies/ml and 29 (74.4%) had ≥ 50 copies/ml. Among patients with baseline VL &lt; 50 copies/ml, 85.7% and 80.0% had VL &lt; 50 copies/ml at 24 and 48 weeks, respectively, and 100% had VL &lt; 200 copies/ml at 24 and 48 weeks. Among patients with baseline VL ≥ 50 copies/ml, 42.3% and 40.9% had VL &lt; 50 copies/ml and 69.2% and 68.2% had VL &lt; 200 copies/ml at 24 and 48 weeks. During the first 48 weeks, no patients changed their treatment due to toxicity, and 4 patients (all with baseline VL ≥ 50 copies/ml) changed due to virological failure.</jats:p> </jats:sec><jats:sec> <jats:title>Conclusions</jats:title> <jats:p>EVG/COB/TFV/FTC + DRV was well tolerated and effective in treatment-experienced patients with undetectable viral load as a simplification strategy, allowing once-daily, two-pill regimen with three antiretroviral drug classes. Effectiveness was low in patients with detectable viral loads.</jats:p> </jats:sec>
  • Zugangsstatus: Freier Zugang